StemCell Therapy

While the broader stock market fell Monday, many biotech shares continued to outperform.

The big mover was TG Therapeutics Inc. TGTX, -6.88% which soared 90% after releasing positive results from its Phase 3 clinical trial of its treatment for high-risk leukemia patients. The stock closed up $4.85 to $10.20 on 33.7 million shares, which is 34 times its daily average. The stock blew through several layers of resistance, but pulled back at the close below resistance from the April high at around $10.50. A breakthrough there should get the stock to $13 and then $15. Support is at the days low of $9.10 and then $8. Short interest of 22 times its average volume could accelerate the advance.

Concert Pharmaceuticals Inc. CNCE, +5.11% rocketed 62% Monday on news that Vertex Pharmaceuticals Inc. VRTX, +0.94% will be acquiring the companys cystic fibrosis drug, CTP-656. The stock closed at $15.64, up $5.99, at around the mid-range of the days action, which bodes well for a follow-through. Volume of 10.5 million shares was more than 85 times its average. Watch for a retest the days intraday high at $18.48, a breakthrough that could get the stock moving to test its highs from November 2015 at just under $25.

Kite Pharma Inc. KITE, +1.90% which we highlighted in our biotech article on Friday, followed through on Monday, up $1.37 to $73.90. FBR Capital mentioned the company in a research note in which it said that potential tax reform and FDA policy changes under President Trump could fuel acquisitions of clinical-stage biotech companies. RBC Capital Markets boosted its price target from $85 to $95. KITE surged last week after the company released a favorable earnings report and positive clinical data on its lead product candidate for treating patients with rare forms of blood cancer. Pulling back slightly on Thursday and Friday, the stock is now in a high-level mini-wedge formation, a break of which could lead to the next target at $90.

Amicus Therapeutics Inc. FOLD, +2.85% was relatively flat on Monday, down just 10 cents to $7.69, but is looking strong. As we noted in our article Friday, the stock rocketed 17% on Wednesday after the company CEOs daughter, Megan Crowley, who has Pompe disease, was highlighted during President Trumps address to Congress Tuesday night. The stock has broken out of a mini-consolidation pattern and across lateral resistance from its December high. At its intraday highs last week, the stock nearly reached the level it was at before its big gap down in December. If it can fill that gap, watch for a move next to $9.50.

Among other biotechs to watch, Supernus Pharmaceuticals Inc. SUPN, +5.30% reached a new all-time at $30.37 on Monday, before closing at $29.75, still up $1 in a down market. The drugmaker has been rallying in the past week since topping analysts forecasts in its fourth-quarter report last Wednesday. Watch for $32-$33 in the short term.

Foundation Medicine Inc. FMI, +2.49% gained $3, or 10.6%, to $31.30 on no news Monday. Stock in the diagnostic cancer analyses company has been up six days in a row since closing at $23.10 on Feb. 24. The rally has broken the stock out of a falling wedge pattern. Our initial target of $29 was exceeded Monday, and next target is near $35.

See Harrys video-chart analysis on these stocks.

The writer has no holdings in any securities mentioned.

Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations.

Link:
Opinion: Harry Boxer's six biotechnology stocks to watch - MarketWatch

This entry was posted on March 9, 2017 at 1:42 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |